Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | PTAFR | P25105 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109969 | 1.00 | MEN1 (0.47) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL10631212 | 1.00 | MEN1 (0.47) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL815193 | 1.00 | MEN1 (0.47) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL814257 | 1.00 | MEN1 (0.47) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL898883 | 0.98 | MEN1 (0.44) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL15686649 | 0.96 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL3103625 | 0.96 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL14971389 | 0.96 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL3230862 | 0.96 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 | |
| SCHEMBL10066970 | 0.96 | MEN1 (0.50) | MEN1KMT2AALDH1A1TDP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9687556-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD. (IL) | 2017-06-27 | — | — | US | disclosed |
| US-20160106855-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106855-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, LNPK, NPC1L1 | MEN1 1557/4885KMT2A 3775/4885ALDH1A1 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.